Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) (OTCPK:ESAIY) announced that the U.S. Food and Drug Administration (FDA) ...

Groundbreaking research reveals how a cancer drug could restore brain function in early Alzheimer's patients by targeting glucose metabolism. Here's what you need to know.

DMTs are expected to account for 73.5% of the global market. The global Alzheimer's disease (AD) market across the eight ...

Discover how dopamine’s unexpected role in breaking down harmful plaques could revolutionize Alzheimer's treatment and ...

Recent studies implicate the immune system and a herpes virus as potential contributors to development of disease ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) said that the U.S. Food and Drug Administration has accepted Eisai's Biologics ...

3, 2024 — What do spiders and Alzheimer's disease have in common ... 2, 2024 — Beta-blocker drugs -- commonly used to treat heart and blood pressure issues -- may slow the progression of ...

Both drugs work by reducing the brain amyloid levels in patients in the early stages of Alzheimer’s, and act to slow the disease. Still, they don’t stop or reverse it, while both treatments ...

There’s intriguing news today about a technology that could improve treatment in people with Alzheimer’s. It uses sound waves ...

(Bloomberg) -- Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025. Companies including Biogen Inc.